NewAmsterdam Pharma vs Xenon Pharmaceuticals
NAMS and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NAMS and XENE compare
NewAmsterdam Pharma grew revenue faster over the last twelve months (−88.9% versus −100% for Xenon Pharmaceuticals).
Xenon Pharmaceuticals scores higher on the StockData Score (7 against 6 for NewAmsterdam Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NAMS | XENE |
|---|---|---|
| Size and price | ||
| Market cap | – | $3.8B |
| Share price | $19.39 | $38.78 |
| Change, 1 year | −49.4% | −4.9% |
| Change, 5 years | 98.1% | 41.3% |
| Beta (5Y) | 1.57 | 0.26 |
| Employees | 100 | 370 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 3.0× |
| FCF yield | – | −9.0% |
| Growth | ||
| Revenue growth (TTM) | −88.9% (better) | −100% |
| Revenue growth, 5Y average | – | −25.3% |
| Profitability | ||
| Operating margin | −3432% | – |
| Net margin | −3644% | – |
| FCF margin | −2018% | – |
| Return on equity | −36.8% (better) | −43.6% |
| Return on invested capital | −1046% | −152% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.03 | 21.02 (better) |
| Altman Z-score | – | 40.35 |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 104% |
| Held by insiders | 22.0% | 0.17% |
| Insider net buying, 12 months | −$63.0M | −$20.3M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 7.6% |
Go deeper
- NAMS stock overview
- NAMS income statement
- NAMS valuation and score
- XENE stock overview
- XENE income statement
- XENE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.